Inspyr is developing new treatments for some of the most challenging areas in oncology, including liver cancer, brain cancer and prostate cancer.

Inspyr's lead investigational agent is mipsagargin (G-202), a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. With positive data from Phase II trials in HCC and with ongoing Phase II trials in other tumor types, mipsagargin is poised to have a tremendous impact on patients who currently have limited cancer treatment options

Inspyr Therapeutics, Inc. Pipeline

Click for Clinical Trials